Druggability Technologies enters into a strategic collaboration with Bayer HealthCare
Dublin Ireland; and Budapest, Hungary 5th December, 2013 – Druggability Technologies (DRGT) today announced that they have entered into a multi-year collaboration agreement with Bayer HealthCare that will deploy DRGT’s proprietary Super-API platform in support of Bayer HealthCare’s formulation efforts directed at improving compound solubility and bioavailability. The agreement calls for the application of DRGT’s platform from early compound screening to clinical formulation of candidate drugs. It is expected that the platform will be applied across a wide range of compounds where such are burdened by low solubility and poor bioavailability. DRGT’s proprietary Super-API platform aims at the acceleration of drug selection and successful development of novel drug candidates.
The terms of the agreement include support and funding the Super-API development platform application to Bayer compounds. It is also anticipated that DRGT will contribute to the manufacture of Bayer HealthCare Super-API constructed compounds during clinical development and in manufacture for sale.
“This is an important collaboration for DRGT, and we are delighted to be working with Bayer, a global leader in the discovery and development of important and novel drugs that significantly improve treatment outcomes and the quality of life of patients” commented Gabor Heltovics, DRGT’s CEO. “We believe that the application of our Super-API technology to the discovery and development portfolio of Bayer will help unlock the full potential of many drug candidates and can deliver clinically important benefits to patients. We are also convinced that this collaboration will bring substantial value and success to our company and our shareholders.”
About Druggability Technologies
Headquartered in Dublin, Ireland with its R&D operation based in Budapest, Hungary, DRGT develops and manufactures proprietary pharmaceutical products that deliver measurable and meaningful benefits in clinical efficacy. This is enabled through the deployment of the Company’s Super-API platform that delivers substantial improvement in compound solubility, permeability and bio-availability resulting in high-value, proprietary products. The corporation was founded by Dr. Ferenc Darvas, Chairman of the oldest Hungarian upstream-technology network.